Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1852W HIGH $6.45
Volume
5.95 M
Value Traded
1.16 M
Short % Float
1.72%
Days to Cover
1.0
+5.89%Week
-13.61%1 Month
-88.3%3 Month
-86.94%6 Month
-96.82%5 Year
-99.76%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
9.52 M
EPS (TTM)
-0.57
P/E Ratio
-
Ent. Value
-100.10 M
Total Shares
47.31 M
Float Shares
44.48 M
Insiders
6.02%
Institutions
68.72%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
EPIX Catalyst Timeline
Dated clinical, regulatory and corporate events for ESSA Pharma Inc.
Past FDA Catalysts and PDUFA Decisions
How EPIX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every EPIX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| masofaniten | metastatic castration-resistant prostate cancer | Phase 2 | 2024-11-01 | much higher rate of PSA90 response in patients treated with enzalutamide monotherapy than were expected based upon historical dataRead More | ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BVF PARTNERS L P/IL10% Owner | Sell | -79 6,194,145 held | $1.88 | 08/05/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in EPIX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BVF INC/IL | 0.1 % (-80 %) | 2.23 M | 11.67 M | 33.37% ( 2.92 M) |
Ownership Trends
EPIX Short Interest
Shares sold short, counted twice a month.
1.72%
Short % of Float
of tradable shares sold short
1.2M
Shares Sold Short
-10.1% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
2.7M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EPIX ranks across every disease it competes in
Competitive Position is a premium feature
See how EPIX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEPIX News
About ESSA Pharma Inc.
Founded13-03-2015
BIOPHARMAWATCH ELITE PLUS
Trade the next EPIX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime